Sanofi India Limited (NSE:SANOFI)

Market Cap	73.00B -38.3%
Revenue (ttm)	18.05B -8.9%
Net Income	3.24B -10.6%
EPS	140.59 -10.6%
Shares Out	n/a
PE Ratio	22.54
Forward PE	18.05
Dividend	123.00 (3.89%)
Ex-Dividend Date	Apr 22, 2026

Volume	13,873
Open	3,155.00
Previous Close	3,155.00
Day's Range	3,134.50 - 3,186.00
52-Week Range	3,054.00 - 5,175.50
Beta	0.20
Analysts	Buy
Price Target	4,339.67 (+36.9%)
Earnings Date	Aug 4, 2026

About Sanofi India

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also expor...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1956
• Employees: 1,097
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SANOFI

Financial Performance

In 2025, Sanofi India's revenue was 18.37 billion, a decrease of -8.73% compared to the previous year's 20.13 billion. Earnings were 3.27 billion, a decrease of -20.99%.

Analyst Summary

According to 3 analysts, the average rating for SANOFI stock is "Buy." The 12-month stock price target is ₹4,340, which is an increase of 36.90% from the latest price.

Price Target

₹4,340

(36.90% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error